Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study

作者全名："Fang, Xia; Wang, Hongya; Ye, Ting; Fu, Xiaolan; Tan, Xiaozhen; Zeng, Yan; Fan, Jiahao; Xu, Yong"

作者地址："[Fang, Xia; Wang, Hongya; Tan, Xiaozhen; Zeng, Yan; Xu, Yong] Southwest Med Univ, Dept Endocrinol & Metab, Affiliated Hosp, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China; [Fang, Xia; Wang, Hongya; Tan, Xiaozhen; Zeng, Yan; Xu, Yong] Cardiovasc & Metab Dis Key Lab Luzhou, Luzhou 646000, Sichuan, Peoples R China; [Fang, Xia; Wang, Hongya; Tan, Xiaozhen; Zeng, Yan; Xu, Yong] Sichuan Clin Res Ctr Nephropathy, Luzhou 646000, Sichuan, Peoples R China; [Ye, Ting] Southwest Med Univ, Dept Lab Med, Affiliated Hosp, Luzhou 646000, Sichuan, Peoples R China; [Fu, Xiaolan] Chongqing Med Univ, Dept Resp Med, Yongchuan Hosp Tradit Chinese Med, Chongqing 402160, Peoples R China; [Fan, Jiahao] Southwest Med Univ, Dept Gastroenterol, Affiliated Hosp, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China"

通信作者："Xu, Y (corresponding author), Southwest Med Univ, Dept Endocrinol & Metab, Affiliated Hosp, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China.; Xu, Y (corresponding author), Cardiovasc & Metab Dis Key Lab Luzhou, Luzhou 646000, Sichuan, Peoples R China.; Xu, Y (corresponding author), Sichuan Clin Res Ctr Nephropathy, Luzhou 646000, Sichuan, Peoples R China.; Fan, JH (corresponding author), Southwest Med Univ, Dept Gastroenterol, Affiliated Hosp, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China."

来源：LIPIDS IN HEALTH AND DISEASE

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000692398000002

JCR分区：Q2

影响因子：4.5

年份：2021

卷号：20

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Maresin-1; Non-alcoholic fatty liver disease; Cross-sectional study; Metabolic diseases; Specialized pro-resolving mediators; Anti-inflammatory cytokines

摘要："Background Maresin-1 (MaR1) is an anti-inflammatory pro-resolving mediator and is considered a potential regulator of metabolic diseases. Non-alcoholic fatty liver disease (NAFLD) is a very common metabolic liver disease. However, little information is available on the relationship between MaR1 and NAFLD in humans. Therefore, the study explored the association between serum MaR1 levels and NAFLD. Methods A cross-sectional study was conducted in 240 Chinese people, including 116 non-NAFLD subjects and 124 NAFLD patients. Serum MaR1 levels were determined by enzyme-linked immunosorbent assay (ELISA). The association between MaR1 and NAFLD was assessed. Results Circulating MaR1 levels in NAFLD patients were markedly lower than those in non-NAFLD subjects (63.63 [59.87-73.93] vs 73.11 [65.12-84.50] pg/mL, P = 0.000). The percentages of patients with NAFLD gradually decreased with the increase of MaR1 quartiles (P < 0.001). Furthermore, serum MaR1 levels were positively associated with aspartate aminotransferase/alanine aminotransferase (AST/ALT), albumin, the albumin-globulin-ratio, and high-density lipoprotein cholesterol (HDL-C) (all P < 0.05) and negatively associated with body mass index (BMI), waist circumference, hip circumference, the waist-to-hip ratio, ALT, gamma-glutamyl transpeptidase (GGT), uric acid, triglyceride (TG), and fasting blood glucose (FBG) (all P < 0.05) after adjusting for sex and age. Binary logistic regression analysis revealed that serum MaR1 levels were significantly associated with NAFLD. Conclusions Circulating MaR1 levels were decreased in patients with NAFLD, and a negative correlation was identified between NAFLD and serum MaR1 concentrations. Decreased MaR1 might be involved in the development of NAFLD."

基金机构："Doctor Initiation Fund of the Affiliated Hospital of Southwest Medical University [19064]; Key Project of Natural Science of Southwest Medical University [2020ZRZD004]; Sichuan Science and Technology Program [2019YFS0537, 2020YFS0456]"

基金资助正文："This work was supported by the Doctor Initiation Fund of the Affiliated Hospital of Southwest Medical University [grant no. 19064], the Key Project of Natural Science of Southwest Medical University [grant no. 2020ZRZD004], and the Sichuan Science and Technology Program [grant nos. 2019YFS0537 and 2020YFS0456]."